Immunomedics, Inc. (NASDAQ: IMMU) reported Q2 EPS of $0.27, $0.35 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $11.47 million.

For earnings history and earnings-related data on Immunomedics, Inc. (IMMU) click here.

Earnings